Back to Search
Start Over
The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients.
- Source :
- Diagnostics (2075-4418); Dec2022, Vol. 12 Issue 12, p3042, 27p
- Publication Year :
- 2022
-
Abstract
- Breast cancer is the most common cancer affecting women worldwide. It is a malignant and heterogeneous disease with distinct molecular subtypes, which has prognostic and predictive implications. Circulating tumor DNA (ctDNA), cell-free fragmented tumor-derived DNA in blood plasma, is an invaluable source of specific cancer-associated mutations and holds great promise for the development of minimally invasive diagnostic tests. Furthermore, serial monitoring of ctDNA over the course of systemic and targeted therapies not only allows unparalleled efficacy assessments but also enables the identification of patients who are at risk of progression or recurrence. Droplet digital PCR (ddPCR) is a powerful technique for the detection and monitoring of ctDNA. Due to its relatively high accuracy, sensitivity, reproducibility, and capacity for absolute quantification, it is increasingly used as a tool for managing cancer patients through liquid biopsies. In this review paper, we gauge the clinical utility of ddPCR as a technique for mutational profiling in breast cancer patients and focus on HER2, PIK3CA, ESR1, and TP53, which represent the most frequently mutated genes in breast cancers. [ABSTRACT FROM AUTHOR]
- Subjects :
- CIRCULATING tumor DNA
CANCER patients
BREAST cancer
BRCA genes
INVASIVE diagnosis
Subjects
Details
- Language :
- English
- ISSN :
- 20754418
- Volume :
- 12
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- Diagnostics (2075-4418)
- Publication Type :
- Academic Journal
- Accession number :
- 160983217
- Full Text :
- https://doi.org/10.3390/diagnostics12123042